Background:In this prospective study we compared the efficacy of carbetocin with oxytocin in prevention of uterine atony after normal vaginal delivery along with need of other uterotonics, fall in hemoglobin,side effects and amount of blood loss in both the groups Material and methods:Patients were divided into 2 groups randomly by envelope method into Group A and Group B. During the study Group A women received carbetocin 100 μg I/M as a single dose and Group B women received 10 IU of oxytocin im immediately after delivery. The primary outcome was measured by the amount of blood loss immediately after delivery. Results:In this study, mean age in group C and O was 28.4±3.3 years and 28.1±3.4 years respectively. This difference was not found to be statistically significant.In our study, mean duration of 3rd stage in group C and O was 19.9±4.4 min and 20.9±3.7 min respectively. This difference was not found to be statistically significant.In our study, no statistically significant difference was found in any adverse effect and wascomparable in both the groups.In our study, out of the 75 participants in group C, 3 had primary PPH and out of the 75 participants in group O, 11 had primary PPH. This difference was found to be statistically significant.In our study, mean blood loss in group C and O was 443.3± 38.8 ml and 467.9±46.9 ml respectively. This difference was found to be statistically significant. Conclusion:Our study showed superior results in favor of carbetocin compared to oxytocin. In this study a statistically significant less blood transfusion, less blood loss, less requirement of additional uterotonic and less primary PPH was found in group carbetocin compared to oxytocin group.So, according to the current study, Carbetocin is an effective new drug compared to Oxytocin for prevention of postpartum hemorrhage in vaginal delivery.